Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics
ASMB Stock Summary
- The ratio of debt to operating expenses for Assembly Biosciences Inc is higher than it is for about only 9.6% of US stocks.
- Revenue growth over the past 12 months for Assembly Biosciences Inc comes in at 395.55%, a number that bests 98.24% of the US stocks we're tracking.
- In terms of volatility of its share price, ASMB is more volatile than 95.93% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Assembly Biosciences Inc are PRQR, DRNA, CNCE, AGIO, and QURE.
- Visit ASMB's SEC page to see the company's official filings. To visit the company's web site, go to www.assemblybio.com.
ASMB Stock Price Chart Interactive Chart >
ASMB Price/Volume Stats
|Current price||$4.31||52-week high||$27.84|
|Prev. close||$4.37||52-week low||$4.01|
|Day high||$4.45||Avg. volume||1,205,380|
|50-day MA||$4.86||Dividend yield||N/A|
|200-day MA||$11.29||Market Cap||172.65M|
Assembly Biosciences, Inc. (ASMB) Company Bio
Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.
ASMB Latest News Stream
|Loading, please wait...|
ASMB Latest Social Stream
View Full ASMB Social Stream
Latest ASMB News From Around the Web
Below are the latest news stories about Assembly Biosciences Inc that investors may wish to consider to help them evaluate ASMB as an investment opportunity.
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stocks News Feed
SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05… Read More »Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Ther...
SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05 per share, the closing price of Assembly Bio’s common stock on March 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment. The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in approximately equal monthly installm...
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.
Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive …
ASMB Price Returns
Continue Researching ASMBWant to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:
Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch